Daily Cardiology Research Analysis
Analyzed 182 papers and selected 3 impactful papers.
Summary
Three impactful cardiology papers span interventional, critical care, and mechanistic science. A global randomized trial in diabetes showed a sirolimus-eluting stent (Abluminus DES+) was not non-inferior to XIENCE EES. A Circulation analysis of DanGer Shock suggests the survival benefit of microaxial flow pumps wanes with treatment delay, while mechanistic work in Cardiovascular Research identifies time- and cell state–specific ADAM17 inhibition after MI as a strategy to reduce scar stiffness and promote revascularization.
Research Themes
- Stent performance and device selection in high-risk diabetic CAD
- Timing of hemodynamic support in cardiogenic shock (systems-of-care impact)
- Fibroblast-targeted, temporally optimized modulation of post-MI remodeling
Selected Articles
1. Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial.
In a 74-center randomized trial of 3,032 diabetic patients undergoing PCI, Abluminus DES+ failed to meet non-inferiority to XIENCE EES for 12-month ischaemia-driven target-lesion revascularization and target-lesion failure. Event rates between 12 and 24 months were similar between groups.
Impact: This large, international RCT directly informs device selection in high-risk diabetic CAD by showing higher revascularization with Abluminus DES+ at 12 months. Robust negative results challenge adoption of a newer platform designed for enhanced drug delivery.
Clinical Implications: For diabetic patients requiring PCI, XIENCE EES remains preferable based on lower 12-month revascularization and TLF. Operators should be cautious about adopting Abluminus DES+ and ensure diligent post-PCI secondary prevention regardless of stent choice.
Key Findings
- Abluminus DES+ did not meet non-inferiority to XIENCE EES for 12-month ischaemia-driven TLR (KM estimate 4.8% vs 2.1%; absolute difference 2.7%).
- Non-inferiority was also not met for 12-month target-lesion failure (composite of CV death, target-vessel MI, and ischaemia-driven TLR).
- Event rates from 12 to 24 months were similar between groups.
Methodological Strengths
- Large, multicenter randomized controlled design with concealed allocation and masked event adjudication.
- Pre-specified co-primary non-inferiority endpoints with time-to-event analysis.
Limitations
- Open-label design may influence procedural choices and follow-up testing.
- The non-inferiority margins and operator-dependent techniques (e.g., inflation time) may affect generalizability.
Future Directions: Head-to-head trials assessing mechanistic surrogates (healing, neoatherosclerosis) and longer-term outcomes in diabetics are needed, alongside optimization of drug-delivery kinetics and polymer platforms.
BACKGROUND: In patients with coronary artery disease, diabetes increases the risk of restenosis and adverse cardiovascular events after percutaneous coronary intervention (PCI). The Abluminus DES+ is a thin-strut cobalt-chromium sirolimus-eluting stent (SES) with abluminal and balloon-surface coating intended to enhance drug delivery to the vessel wall. We aimed to compare the efficacy and safety of the Abluminus DES+ SES versus the XIENCE durable-polymer everolimus-eluting stent (EES) in patients with diabetes undergoing PCI. METHODS: ABILITY Diabetes Global was a multicentre, prospective, open-label, randomised controlled trial conducted at 74 sites in 16 countries. Adults (aged ≥18 years) with type 1 or type 2 diabetes undergoing PCI for at least one de novo coronary lesion due to chronic coronary syndrome or non-ST-elevation acute coronary syndrome were eligible. Patients were randomly assigned (1:1) to the Abluminus DES+ SES or the XIENCE EES. Randomisation was stratified by site using a secure web-based system with concealed allocation and randomly varying block sizes (4, 6, and 8). Operators were unmasked to allocation; staff performing clinical follow-up and the independent clinical events committee were masked. For the Abluminus DES+ SES, a balloon inflation time of at least 45 s was recommended to facilitate drug transfer; dual antiplatelet therapy was prescribed to all patients according to clinical guidelines and local practice. The primary hypothesis of the study was the non-inferiority of the Abluminus DES+ SES compared with the XIENCE EES for the two coprimary endpoints at 12 months (in the per-protocol population): ischaemia-driven target-lesion revascularisation (2·8% non-inferiority margin) and target-lesion failure (3·0% margin), defined as a composite of cardiovascular death, target-vessel myocardial infarction, or ischaemia-driven target-lesion revascularisation. Time-to-event analyses were conducted with Kaplan-Meier estimates and Cox proportional hazards models. This trial is registered with ClinicalTrials.gov (NCT04236609) and is complete. FINDINGS: Between June 12, 2020, and Sept 9, 2022, 3032 patients were randomly assigned to the Abluminus DES+ SES (n=1514) or XIENCE EES (n=1518). 2931 (96·7%) of 3032 patients completed follow-up to death or 24-month follow-up. Median age was 68·0 years (IQR 60-74). 879 (29·0%) of 3032 patients were female and 2153 (71·0%) were male. At 12 months, in the per-protocol analysis, the Abluminus DES+ SES did not meet the criteria for non-inferiority for ischaemia-driven target-lesion revascularisation compared with XIENCE EES (67 of 1421 patients [Kaplan-Meier estimate 4·8%, 95% CI 3·9-6·2] vs 30 of 1446 [2·1%, 95% CI 1·6-3·2]; absolute risk difference 2·7%, 95% CI 1·3-4·1; p
2. Temporal inhibition of ADAM17 in fibroblasts reduces stiffness and promotes vascularization following myocardial infarction.
ADAM17 expression rises in infarct myofibroblasts. Conditional knockdown revealed that ADAM17 is required early in homeostatic fibroblasts for infarct integrity, but its persistent activity in myofibroblasts stiffens scar and worsens remodeling. Short-term post-MI ADAM17 inhibition reduced scar stiffness, enhanced VEGFR-driven vascularization, and limited LV dilation and dysfunction.
Impact: This study identifies a time- and cell state–specific therapeutic window for ADAM17 inhibition after MI, revealing a mechanism to improve scar compliance and revascularization. It reframes fibroblast-targeted therapy with precise temporal control.
Clinical Implications: Although preclinical, the work supports short, early post-MI ADAM17 inhibition to prevent adverse remodeling while avoiding pre-MI or early FB inhibition that risks rupture. It informs the design of temporally targeted anti-fibrotic strategies.
Key Findings
- ADAM17 is upregulated in infarct myofibroblasts and its loss in homeostatic fibroblasts compromises infarct integrity with increased LV rupture.
- myoFB-specific ADAM17 loss decreased scar stiffness via EGFR/YAP pathway suppression, enhanced VEGFR signaling, endothelial proliferation, and vascularization, limiting infarct expansion and LV dilation up to 4 weeks post-MI.
- Pharmacologic ADAM17 inhibition was ineffective before MI but effective when administered short-term after MI, mirroring genetic findings.
Methodological Strengths
- Dual inducible, cell type–specific genetic models with convergent in vitro, ex vivo, RNA-seq, and human tissue validation.
- Mechanistic pathway dissection (EGFR/YAP, VEGFR) with functional readouts (stiffness, vascularization, LV remodeling).
Limitations
- Preclinical models; translational dosing, safety, and long-term outcomes remain untested in humans.
- Pharmacologic inhibitor specificity and optimal timing/duration require further definition.
Future Directions: Translate to early-phase clinical studies testing short-course ADAM17 inhibition post-MI with imaging biomarkers of scar mechanics and perfusion; refine cell-targeting and timing in large animals.
AIMS: Myocardial infarction (MI) triggers a complex remodeling that, if uncontrolled, leads to heart failure. Increased levels of ADAM17 (disintegrin and metalloproteinase-17) in ischemic injury has been reported, but its direct role in scar formation and subsequent recovery from MI has not been identified. We investigated the role of ADAM17 in the function of homeostatic fibroblasts (FBs) vs. activated myofibroblasts (myoFBs) in scar formation, and recovery following MI. METHODS AND RESULTS: Human myocardial specimens showed upregulated ADAM17 in the infarct tissue, colocalized to myofibroblasts. We generated two inducible genetic mouse models with Adam17 knockdown in FBs (Adam17FB-KD) or myoFB (Adam17myoFB-KD) and subjected them to MI. Loss of ADAM17 in FBs impaired infarct formation and increased mortality due to left ventricular (LV) rupture in males and females. In contrast, ADAM17 loss in myoFBs limited infarct expansion, LV dilation and dysfunction up to 4-wks post-MI. Macrophage infiltration was suppressed in both genotypes. Ex vivo and in vitro experiments revealed that loss of ADAM17 in myoFB resulted in scar tissue with reduced stiffness due to suppressed activation of epidermal growth factor receptor and the Yes-associated protein (YAP) pathway. This promoted VEGFR signaling, endothelial cell (EC) proliferation, and vascularization in the infarcted myocardium, limiting infarct expansion. RNAseq analyses showed drastic changes in extracellular matrix (ECM) genes in Adam17KD FB and myoFBs in hypoxia. In vitro co-culture of myoFB and ECs confirmed that the ECM deposited by Adam17-deficient myoFB promotes EC proliferation and sprouting. Pharmacological inhibition of ADAM17 before MI was ineffective, but short-term ADAM17 inhibition after MI (targeting the myoFBs), limited infarct expansion, LV dilation and dysfunction up to 4-weeks post-MI. CONCLUSION: Short-term inhibition of ADAM17 after MI optimizes the compliance of the infarct tissue, promoting vascularization, limiting infarct expansion, preventing long-term adverse LV remodeling, dysfunction, and heart failure. Targeting the homeostatic FB vs. myoFB also highlights the critical timing of ADAM17 inhibition as its presence is essential for the initial healing of the infarcted heart, but inhibition of its persistent upregulation reduces scar stiffness and improves the outcome post-MI.
3. Delay From First Symptoms in Patients Presenting With STEMI and Cardiogenic Shock: Insights From the DanGer Shock Trial.
In a secondary analysis of the DanGer Shock randomized trial (n=345), 180-day mortality rose stepwise with longer delay from symptom onset to randomization. Although microaxial flow pump therapy reduced all-cause mortality overall, its benefit appeared attenuated with prolonged delays.
Impact: These findings highlight the time-sensitive nature of mechanical support in STEMI shock, underscoring system-level priorities for rapid recognition, transfer, and early device deployment.
Clinical Implications: Regional networks should minimize delays from symptom onset to device initiation to maximize survival benefit; triage protocols and early activation of shock teams and device-capable centers are critical.
Key Findings
- Across quartiles of symptom-to-randomization delay, 180-day mortality increased: 36%, 53%, 59%, and 62%.
- Microaxial flow pump therapy was associated with reduced all-cause mortality overall, but benefit weakened with longer delays.
- The analysis emphasizes the importance of early recognition and rapid randomization/device initiation in STEMI shock.
Methodological Strengths
- Secondary analysis of a multicenter randomized trial with standardized 180-day endpoint.
- Systematic stratification by symptom-to-randomization time, enabling time–treatment effect assessment.
Limitations
- Secondary, post hoc analysis may be subject to residual confounding and is not powered for interaction testing.
- Delay measured to randomization may not precisely capture time to device implantation in all cases.
Future Directions: Prospective protocols prioritizing prehospital identification and expedited device initiation should be tested; health-system implementation studies to reduce delays are warranted.
BACKGROUND: Microaxial flow pump (mAFP) use in selected patients with ST-segment-elevation myocardial infarction complicated by cardiogenic shock improves survival. The present study aimed to assess the influence of delay from first symptoms to randomization on the benefit of an mAFP in patients with ST-segment-elevation myocardial infarction complicated by cardiogenic shock. METHODS: This was a secondary analysis of the international, multicenter, randomized, open-labeled DanGer Shock trial (Danish-German Cardiogenic Shock). A total of 345 of 355 patients with ST-segment-elevation myocardial infarction and cardiogenic shock were enrolled in this substudy. Patients were stratified into quartiles according to delay from first symptoms to randomization to either an mAFP or standard care alone. The end point was death from any cause at 180 days for treatment with an mAFP versus standard of care, according to time from onset of symptoms to randomization obtained by logistic regression analysis. RESULTS: Mortality at 180 days increased across quartiles of time from onset of symptoms to randomization: Q1 (0-140 minutes), 36%; Q2 (141-248 minutes), 53%; Q3 (249-650 minutes), 59%; and Q4 (> 651 minutes), 62%, respectively (log-rank CONCLUSIONS: In patients with ST-segment-elevation myocardial infarction complicated with cardiogenic shock, treatment with an mAFP was associated with reduced all-cause mortality, but the treatment benefit appeared to weaken with prolonged time from the onset of symptoms to randomization. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01633502.